M1 Kliniken AG investor news & press releases

| Investor News

M1 Kliniken AG announces figures for the first quarter of 2021. According to these figures, the consolidated group revenue of the M1 Group in the first quarter of the financial year 2021 rose by approx. 250% year-on-year to just under EUR 81 million (previous year: EUR 23 million). Of this, HAEMATO AG (without M1 Aesthetics), which was not yet consolidated in the same period of the previous year, accounted for sales of a good EUR 59 million.

| Investor News

M1 Kliniken AG publishes preliminary figures for the financial year 2020. In the past financial year, the M1 Group was able to maintain its market leadership in Germany in the field of aesthetic medicine and - despite considerable burdens due to pandemic-related closures of clinics - generated a clearly positive operating result. In addition, the acquisition of Haemato AG laid the foundation for the development and expansion of the private label business.

M1 Kliniken AG (ISIN: DE000A0STSQ8) publishes preliminary figures for the financial year 2020. In the past financial year, the M1 Group was able to maintain its market leadership in Germany in the field of aesthetic medicine and - despite considerable burdens due to pandemic-related closures of clinics - generated a clearly positive operating result. In addition, the acquisition of Haemato AG laid the foundation for the development and expansion of the private label business.

| Investor News

M1 Kliniken AG and HAEMATO AG today signed a contract for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contribution in kind.

| Ad-hoc news

M1 Kliniken AG and HAEMATO AG today signed a contract for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contribution in kind.

| Ad-hoc news

M1 Kliniken AG announces that as of today Mr. Patrick Brenske will join the Management Board of HAEMATO AG. At the same time, Mr. Brenske will resign from the Management
Board of M1 Kliniken AG, with Dr. Walter von Horstig from now on acting as sole member of the Management Board. Mr. Brenske will continue to advise M1.

| Investor News

In contrast to the worsening pandemic situation, M1 Kliniken AG continues to record strong demand. The number of injection treatments and surgical treatments performed in the German market in the 3rd quarter of 2020 rose by almost 20% year-on-year to over 65,000.

| Investor News

  • Group revenues decrease by only 12 % to 29.1 million Euro despite loss of about 1/3 of treatment days
  • Consolidated net income of 2.0 million Euro
  • High utilization of the specialized centers after resumption of patient treatments

| Investor News

Yesterday, M1 Kliniken AG successfully held its Annual General Meeting 2020. In his presentation, the Management Board gave an outline of the company's prosperous development in the 2019 financial year, which was accompanied by a significant …

| Investor News

M1 Kliniken AG acquires about 48 % of the share capital of HAEMATO AG from MPH Health Care AG. Transfer of the HAEMATO shares within the framework of a capital increase through contribution in kind Focus of both companies on their respective core …

| Ad-hoc news

M1 Kliniken AG acquires ca. 48% of the shares of HAEMATO AG - transfer of the shares in a capital increase against contribution in kind of M1 Kliniken AG

| Investor News

M1 Kliniken AG today published its consolidated financial statements for 2019. The M1 Group has increased its consolidated revenue by 18% to EUR 77.2 million (previous year: EUR 65.2 million) in the financial year 2019. The consolidated net profit for the year increased by 47% to 9.7 million euros.